Cargando…

Incidence of blast phase in myelofibrosis according to anemia severity

Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%–20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and ‐in primary MF‐ also with an increased probability of BP. Conventional treatments for anemia have limited eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora, Barbara, Maffioli, Margherita, Rumi, Elisa, Guglielmelli, Paola, Caramella, Marianna, Kuykendall, Andrew, Palandri, Francesca, Iurlo, Alessandra, De Stefano, Valerio, Kiladjian, Jean‐Jacques, Elli, Elena M., Polverelli, Nicola, Gotlib, Jason, Albano, Francesco, Silver, Richard T., Benevolo, Giulia, Ross, David M., Devos, Timothy, Borsani, Oscar, Barbui, Tiziano, Porta, Matteo G. Della, Bertù, Lorenza, Komrokji, Rami, Vannucchi, Alessandro M., Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435699/
https://www.ncbi.nlm.nih.gov/pubmed/37601878
http://dx.doi.org/10.1002/jha2.745
_version_ 1785092160820871168
author Mora, Barbara
Maffioli, Margherita
Rumi, Elisa
Guglielmelli, Paola
Caramella, Marianna
Kuykendall, Andrew
Palandri, Francesca
Iurlo, Alessandra
De Stefano, Valerio
Kiladjian, Jean‐Jacques
Elli, Elena M.
Polverelli, Nicola
Gotlib, Jason
Albano, Francesco
Silver, Richard T.
Benevolo, Giulia
Ross, David M.
Devos, Timothy
Borsani, Oscar
Barbui, Tiziano
Porta, Matteo G. Della
Bertù, Lorenza
Komrokji, Rami
Vannucchi, Alessandro M.
Passamonti, Francesco
author_facet Mora, Barbara
Maffioli, Margherita
Rumi, Elisa
Guglielmelli, Paola
Caramella, Marianna
Kuykendall, Andrew
Palandri, Francesca
Iurlo, Alessandra
De Stefano, Valerio
Kiladjian, Jean‐Jacques
Elli, Elena M.
Polverelli, Nicola
Gotlib, Jason
Albano, Francesco
Silver, Richard T.
Benevolo, Giulia
Ross, David M.
Devos, Timothy
Borsani, Oscar
Barbui, Tiziano
Porta, Matteo G. Della
Bertù, Lorenza
Komrokji, Rami
Vannucchi, Alessandro M.
Passamonti, Francesco
author_sort Mora, Barbara
collection PubMed
description Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%–20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and ‐in primary MF‐ also with an increased probability of BP. Conventional treatments for anemia have limited effectiveness in MF. Within a dataset of 1752 MF subjects largely unexposed to ruxolitinib (RUX), BP incidence was 2.5% patients per year (p‐y). This rate reached respectively 4.3% and 4.5% p‐y in case of patients with common terminology criteria for adverse events (CTCAE) grade 3/4 and grade 2 anemia, respectively, that represented together 32% of the cohort. Among 273 MF cases treated with RUX, BP incidence was 2.89% p‐y and it reached 4.86% p‐y in subjects who started RUX with CTCAE grade 2 anemia (one third of total). Within patients with red blood cell transfusion‐dependency at 6 months of RUX (21% of the exposed), BP rate was 4.2% p‐y. Our study highlights a relevant incidence of BP in anemic MF patients, with a similar rate whether treated with or without RUX. These findings will help treating physicians to make decisions on the safety profile of innovative anemia treatments.
format Online
Article
Text
id pubmed-10435699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104356992023-08-19 Incidence of blast phase in myelofibrosis according to anemia severity Mora, Barbara Maffioli, Margherita Rumi, Elisa Guglielmelli, Paola Caramella, Marianna Kuykendall, Andrew Palandri, Francesca Iurlo, Alessandra De Stefano, Valerio Kiladjian, Jean‐Jacques Elli, Elena M. Polverelli, Nicola Gotlib, Jason Albano, Francesco Silver, Richard T. Benevolo, Giulia Ross, David M. Devos, Timothy Borsani, Oscar Barbui, Tiziano Porta, Matteo G. Della Bertù, Lorenza Komrokji, Rami Vannucchi, Alessandro M. Passamonti, Francesco EJHaem Haematologic Malignancy ‐ Myeloid Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%–20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and ‐in primary MF‐ also with an increased probability of BP. Conventional treatments for anemia have limited effectiveness in MF. Within a dataset of 1752 MF subjects largely unexposed to ruxolitinib (RUX), BP incidence was 2.5% patients per year (p‐y). This rate reached respectively 4.3% and 4.5% p‐y in case of patients with common terminology criteria for adverse events (CTCAE) grade 3/4 and grade 2 anemia, respectively, that represented together 32% of the cohort. Among 273 MF cases treated with RUX, BP incidence was 2.89% p‐y and it reached 4.86% p‐y in subjects who started RUX with CTCAE grade 2 anemia (one third of total). Within patients with red blood cell transfusion‐dependency at 6 months of RUX (21% of the exposed), BP rate was 4.2% p‐y. Our study highlights a relevant incidence of BP in anemic MF patients, with a similar rate whether treated with or without RUX. These findings will help treating physicians to make decisions on the safety profile of innovative anemia treatments. John Wiley and Sons Inc. 2023-07-17 /pmc/articles/PMC10435699/ /pubmed/37601878 http://dx.doi.org/10.1002/jha2.745 Text en © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Haematologic Malignancy ‐ Myeloid
Mora, Barbara
Maffioli, Margherita
Rumi, Elisa
Guglielmelli, Paola
Caramella, Marianna
Kuykendall, Andrew
Palandri, Francesca
Iurlo, Alessandra
De Stefano, Valerio
Kiladjian, Jean‐Jacques
Elli, Elena M.
Polverelli, Nicola
Gotlib, Jason
Albano, Francesco
Silver, Richard T.
Benevolo, Giulia
Ross, David M.
Devos, Timothy
Borsani, Oscar
Barbui, Tiziano
Porta, Matteo G. Della
Bertù, Lorenza
Komrokji, Rami
Vannucchi, Alessandro M.
Passamonti, Francesco
Incidence of blast phase in myelofibrosis according to anemia severity
title Incidence of blast phase in myelofibrosis according to anemia severity
title_full Incidence of blast phase in myelofibrosis according to anemia severity
title_fullStr Incidence of blast phase in myelofibrosis according to anemia severity
title_full_unstemmed Incidence of blast phase in myelofibrosis according to anemia severity
title_short Incidence of blast phase in myelofibrosis according to anemia severity
title_sort incidence of blast phase in myelofibrosis according to anemia severity
topic Haematologic Malignancy ‐ Myeloid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435699/
https://www.ncbi.nlm.nih.gov/pubmed/37601878
http://dx.doi.org/10.1002/jha2.745
work_keys_str_mv AT morabarbara incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT maffiolimargherita incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT rumielisa incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT guglielmellipaola incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT caramellamarianna incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT kuykendallandrew incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT palandrifrancesca incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT iurloalessandra incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT destefanovalerio incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT kiladjianjeanjacques incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT ellielenam incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT polverellinicola incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT gotlibjason incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT albanofrancesco incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT silverrichardt incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT benevologiulia incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT rossdavidm incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT devostimothy incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT borsanioscar incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT barbuitiziano incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT portamatteogdella incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT bertulorenza incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT komrokjirami incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT vannucchialessandrom incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity
AT passamontifrancesco incidenceofblastphaseinmyelofibrosisaccordingtoanemiaseverity